Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

Many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin. But some people with moderate or severe plaque psoriasis have symptoms that do ...

In September 2022, the US Food and Drug Administration (FDA) approved Sotyktu (deucravacitinib; Bristol-Myers Squibb Company), a tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate to ...

Dec. 16, 2003 — Efalizumab improves clinical end points for patients with severe plaque psoriasis, according to the results of a phase III, double-blind trial published in the Dec. 17 issue of The ...

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.